SEC ownership of Syros Pharmaceuticals, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001556263.

Comparable stake leader

Avidity Partners Management LP

Disclosed value leader

Invus Global Management, LLC

Comparable rows

5/19

Latest evidence

31 Dec 2024

Top shareholders Insider holders Latest transactions

Parsed ownership sources: 13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: Avidity Partners Management LP
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 5 of 19
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: Avidity Partners Management LP
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 31 Dec 2024
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001556263
Issuer location: Cambridge, MA

Ownership snapshot

Top shareholders of Syros Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Avidity Partners Manageme...

Disclosed value leader

Invus Global Management, LLC

Comparable rows

5/19

Latest evidence

31 Dec 2024

13D/G 3/4/5 Lead comparable stake: 7.6% 14 rows are not safely comparable across share classes. 13D/G row: Avidity Partners Management LP Showing 1-8 of 19 holder rows.

Quick read

Avidity Partners Management LP leads the comparable SEC ownership view at 7.6%.

5 of 19 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Avidity Partners Management LP's linked filing trail.

Comparable ownership Top 5

Avidity Partners Management LP 7.6%

Invus Global Management, LLC 3.8%

Samsara BioCapital, L.P. 2.6%

ADAGE CAPITAL PARTNERS GP, L.L.C. 2%

Point72 Asset Management, L.P. 0%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 19 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Avidity Partners Management LP	13D/G 13D/G	7.6%	$61,441 2,048,020 shares	$0	31 Dec 2024
Invus Global Management, LLC	13D/G Invus Public Equities, L.P. 13D/G	3.8%	$776,595 1,063,829 shares	$0	31 Dec 2024
Samsara BioCapital, L.P.	13D/G 13D/G	2.6%	$21,213 707,114 shares	$0	18 Nov 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.	13D/G Adage Capital Management, L.P. 13D/G	2%	$15,957 531,914 shares	$0	31 Dec 2024
Point72 Asset Management, L.P.	13D/G 13D/G	0%	$14.88 496 shares	$0	31 Dec 2024
Timothy Tyson	3/4/5 Director 3/4/5	— mixed-class rows	$164,286 39,189 shares mixed-class rows	—	05 Jun 2024
Andrew M. Oh	3/4/5 Director 3/4/5	— mixed-class rows	$79,200 22,000 shares mixed-class rows	—	05 Jun 2024
Deborah Dunsire	3/4/5 Director 3/4/5	— mixed-class rows	$79,200 22,000 shares mixed-class rows	—	05 Jun 2024

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 28 Sep 2025.

Buys

Insiders: 0

Sells

Insiders: 0

Net

Shares: 0

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 0

Window (months)	Buy value	Sell value	Net value
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-18 of 18 reporting-owner rows connected to Syros Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Timothy Tyson

Net 12M change

Latest report

02 Dec 2024

Name	Relationship	Holdings Value	Valuation	Report Date
Timothy Tyson	Director	$164,286	Mixed	05 Jun 2024
Marsha Fanucci	Director	$79,200	Mixed	05 Jun 2024
WIRTH PETER	Director	$79,200	Mixed	05 Jun 2024
Deborah Dunsire	Director	$79,200	Mixed	05 Jun 2024
Sue Gail Eckhardt	Director	$79,200	Mixed	05 Jun 2024
Andrew M. Oh	Director	$79,200	Mixed	05 Jun 2024
Gerald E. Quirk	Chief Legal & Compliance Offic	$33,524	Mixed	19 Nov 2024
Eric R. Olson	Chief Scientific Officer	$29,442	Mixed	17 Jul 2023
Mark J. Alles	Director	$28,045	Mixed	16 Sep 2023
Richard A. Young	Director	$22,350	Mixed	16 Sep 2024
Srinivas Akkaraju	Director	$20,114	Mixed	16 Sep 2024
Nancy A. Simonian	Director	$1,081	Filing P/S	02 Dec 2024
David Roth	Chief Medical Officer	$0	Mixed	18 Nov 2024
Kristin Stephens	Chief Development Officer	$0	Mixed	18 Nov 2024
Conley Chee	President & CEO, Director	$0	Mixed	18 Nov 2024
Jason Haas	Chief Financial Officer	$0	Mixed	18 Nov 2024
Amir Nashat	Director		Mixed	01 Jun 2022
Phillip A. Sharp	Director		Mixed	01 Jun 2022

Recent insider transactions for Syros Pharmaceuticals, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

^* marks a reported price that did not pass the local price check.